In the last trading session, 5.49 million TG Therapeutics Inc (NASDAQ:TGTX) shares changed hands as the company’s beta touched 2.20. With the company’s per share price at $30.91 changed hands at $0.17 or 0.55% during last session, the market valuation stood at $4.81B. TGTX’s last price was a discount, traded about -0.03% off its 52-week high of $30.92. The share price had its 52-week low at $9.81, which suggests the last value was 68.26% up since then. When we look at TG Therapeutics Inc’s average trading volume, we note the 10-day average is 4.51 million shares, with the 3-month average coming to 3.60 million.
Analysts gave the TG Therapeutics Inc (TGTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TGTX as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TG Therapeutics Inc (NASDAQ:TGTX) trade information
Instantly TGTX was in green as seen at the end of in last trading. With action 19.53%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 80.97%, with the 5-day performance at 19.53% in the green. However, in the 30-day time frame, TG Therapeutics Inc (NASDAQ:TGTX) is 35.39% up. Looking at the short shares, we see there were 32.48 million shares sold at short interest cover period of 7.76 days.
The consensus price target for the stock as assigned by Wall Street analysts is 23, meaning bulls need a downside of -34.39% from its current market value. According to analyst projections, TGTX’s forecast low is 16 with 55 as the target high. To hit the forecast high, the stock’s price needs a -77.94% plunge from its current level, while the stock would need to tank 48.24% for it to hit the projected low.
TG Therapeutics Inc (TGTX) estimates and forecasts
Data shows that the TG Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 72.10% over the past 6 months, a 88.89% in annual growth rate that is considerably higher than the industry average of 14.10%.
The 2024 estimates are for TG Therapeutics Inc earnings to decrease by -40.74%.
TGTX Dividends
TG Therapeutics Inc is expected to release its next quarterly earnings report in December.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.53% of TG Therapeutics Inc shares while 61.89% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 68.40%. There are 61.89% institutions holding the TG Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 9.3645% of the shares, roughly 13.69 million TGTX shares worth $243.58 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.7891% or 11.39 million shares worth $202.6 million as of 2024-06-30.
